AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 228 filers reported holding AXSOME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $535,078 | +4.9% | 7,656 | +7.9% | 0.00% | +100.0% |
Q2 2023 | $510,062 | +21.8% | 7,098 | +4.6% | 0.00% | 0.0% |
Q1 2023 | $418,746 | -29.6% | 6,789 | -12.0% | 0.00% | -50.0% |
Q4 2022 | $595,058 | +100.4% | 7,715 | +15.7% | 0.00% | +100.0% |
Q3 2022 | $297,000 | +24.3% | 6,668 | +6.6% | 0.00% | 0.0% |
Q2 2022 | $239,000 | -36.8% | 6,253 | -31.4% | 0.00% | 0.0% |
Q1 2022 | $378,000 | -12.1% | 9,118 | -19.9% | 0.00% | 0.0% |
Q4 2021 | $430,000 | +12.3% | 11,383 | -1.9% | 0.00% | 0.0% |
Q3 2021 | $383,000 | -59.3% | 11,608 | -16.8% | 0.00% | -66.7% |
Q2 2021 | $942,000 | +32.3% | 13,958 | +11.0% | 0.00% | +50.0% |
Q1 2021 | $712,000 | -26.5% | 12,572 | +5.6% | 0.00% | -50.0% |
Q4 2020 | $969,000 | +44.6% | 11,900 | +26.6% | 0.00% | +33.3% |
Q3 2020 | $670,000 | -16.0% | 9,402 | -3.0% | 0.00% | -25.0% |
Q2 2020 | $798,000 | +114.5% | 9,693 | +53.2% | 0.00% | +33.3% |
Q1 2020 | $372,000 | -66.9% | 6,328 | -41.8% | 0.00% | -40.0% |
Q4 2019 | $1,124,000 | – | 10,873 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |